LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2026

SALT LAKE CITY, UT – LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, reported financial results for its third fiscal quarter ended March 31, 2026.

Third Quarter Fiscal 2026 Summary*:

• Revenue was $43.7 million, a decrease of 25.2% from the prior year period;
• Revenue in the Americas decreased 28.9%, and revenue in Asia/Pacific & Europe decreased 7.7%;
• Net income per diluted share was $0.11, versus $0.26 per diluted share a year ago;
• Adjusted earnings per diluted share was $0.12, compared to $0.26 a year ago; and
• Adjusted EBITDA was $3.2 million compared to $6.4 million a year ago.

_{* All comparisons are on a year over year basis and compare the third quarter of fiscal 2026 to the third quarter of fiscal 2025, unless otherwise noted.}

Michael Beindorff, Interim CEO of LifeVantage, said:

“Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 System^® were only partially offset by the addition of LoveBiome. Despite top-line headwinds, we remained focused on managing expenses and allocating capital, enabling us to continue repurchasing shares while maintaining a strong balance sheet and cash position. That said, we are not satisfied with our performance and are laser focused on making the changes necessary to improve results going forward. With our science-backed approach to nutrigenomics, diversified product portfolio, passionate consultant community, and strong financial foundation, LifeVantage is in a compelling position in the rapidly expanding health and wellness market with significant growth potential ahead, and we intend to realize that potential.”

Third Quarter Fiscal 2026 Results

For the third quarter ended March 31, 2026, the Company reported revenue of $43.7 million, a 25.2% decrease compared to revenue of $58.4 million in the third quarter of fiscal 2025. Revenue in the Americas region for the third quarter of fiscal 2026 decreased 28.9% primarily due to declines in sales of the MindBody GLP-1 System^®, partially offset by sales of LoveBiome, which the Company acquired in October 2025. Revenue in the Asia/Pacific & Europe region decreased 7.7%; on a constant currency basis, revenue in the Asia/Pacific & Europe region decreased approximately 8.9%.

Gross profit for the third quarter of fiscal 2026 was $34.5 million, or 79.0% of revenue, compared to $47.3 million, or 81.0% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System^®, along with increases in shipping and warehouse related expenses. Adjusted for the allowance for inventory obsolescence, non-GAAP gross profit was $34.7 million, or 79.4% of revenue.

Commissions and incentives expense for the third quarter of fiscal 2026 was $19.0 million, or 43.5% of revenue, compared to $26.2 million, or 44.8% of revenue, for the same period in fiscal 2025. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year period is primarily due to the timing and magnitude of promotional and incentive programs and changes to the mix of customers and independent consultants in our overall Active Accounts.

Selling, general and administrative (SG&A) expense for the third quarter of fiscal 2026 was $13.9 million, or 31.7% of revenue, compared to $17.1 million, or 29.2% of revenue, for the same period in fiscal 2025. The increase in SG&A expenses as a percentage of revenue was primarily due to the overall decrease in sales volume.

Operating income for the third quarter of fiscal 2026 was $1.7 million compared to $4.1 million for the third quarter of fiscal 2025. Adjusted non-GAAP operating income for the third quarter of fiscal 2026 was $1.8 million compared to adjusted non-GAAP operating income of $4.1 million for the third quarter of fiscal 2025.

Net income for the third quarter of fiscal 2026 was $1.4 million, or $0.11 per diluted share, compared to $3.5 million, or $0.26 per diluted share for the third quarter of fiscal 2025. Adjusted non-GAAP net income for the third quarter of fiscal 2026 was $1.5 million, or $0.12 per diluted share, compared to adjusted non-GAAP income of $3.5 million, or $0.26 per diluted share, for the third quarter of fiscal 2025.

Adjusted EBITDA was $3.2 million for the third quarter of fiscal 2026, versus $6.4 million for the comparable period in fiscal 2025.

View LifeVantage’s Third Quarter Fiscal 2026 full report

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 System^®, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

SOURCE: LifeVantage